Phibro Animal Health and Rejuvenate Bio agree to develop a gene therapy for mitral valve disease in dogs

Rejuvenate Bio/Canine mitral valve disease gene therapy

Phibro Animal Health and Rejuvenate Bio agreed to develop and commercialize a gene therapy for mitral valve disease in dogs, a common heart condition that can lead to heart failure. MVD affects about 7% of all dogs and up to 80% of certain breeds like Cavalier King Charles Spaniels; current therapies slow progression but cannot stop or reverse the disease.

• Mitral valve disease affects ~7% of all dogs, up to 80% in breeds like Cavalier King Charles Spaniels.
• Current therapies slow MVD progression but cannot stop the disease or reverse damage.
• Gene therapy aims to stop MVD before heart failure develops and reverse some or all heart damage.
• Companies expected to file for conditional approval as early as 2023.